Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart? - 2What to know about Jack Dorsey's new Vine revival, DiVine
- 3Four countries to boycott Eurovision 2026 over Israel’s inclusion
- 4Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- 5Four Dead in Last Month From Animal Attacks in Nepal
- British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- Sixteen Kenyans missing in Russia after army recruitment
- Computerized Moderation: Tracking down Equilibrium in the Advanced Age
- Disney's latest short film 'Versa' tackles a difficult subject: Pregnancy loss. It's resonating with viewers.
- Merz: 80% of Syrians in Germany expected to return within three years
- Sexual violence part of 'everyday life' in parts of Sudan, charity says
- NASA's Artemis II launch leaves Americans in awe: 'We're going back to the frickin' moon!'
- Moscow accuses Berlin of stifling the opposition
- Louisiana seeks California doctor’s extradition, testing the limits of shield laws
